#USA #San Diego #Inhibrx #ozekibart #INBRX-106

Inhibrx Biosciences Update: Progress on INBRX-106 and Ozekibart

Inhibrx Biosciences, Inc. (Nasdaq: INBX), a biopharmaceutical firm focused on innovative oncology treatments, has recently shared valuable progress updates regarding its clinical trials for INBRX-106 and ozekibart (INBRX-109). The company is working diligently to develop effective therapeutics for patients battling various types of cancer.

INBRX-106 Clinical Trial Developments

The company announced noteworthy advancements in the Phase 2/3 clinical trial of INBRX-106, which is being tested in combination with Keytruda® (pembrolizumab) for patients suffering from locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC). So far, 46 out of 60 patients have been successfully recruited for the randomized Phase 2 segment of this trial. Enrollment is expected to be completed during the first quarter of 2026.

The trial specifically targets patients with PD-L1 CPS expression equal to or greater than 20, who have not previously received systemic therapy. Participants are randomly assigned to either receive INBRX-106 alongside Keytruda or Keytruda alone. The primary outcome being studied is the overall response rate, which is further supported by secondary endpoints, including duration of response, progression-free survival, and safety assessments.

In parallel, Inhibrx has also finalized enrollment for a Phase 1/2 trial focusing on patients with checkpoint inhibitor refractory or relapsed non-small cell lung cancer (NSCLC), which includes a cohort of 34 patients. This trial explores the synergy between INBRX-106 and Keytruda, aiming to assess objective response rates, disease control rates, duration of response, and safety.

While the information gathered from the datasets regarding HNSCC and NSCLC lacks enough maturity for definitive conclusions, Inhibrx anticipates having adequate data for evaluation by the latter half of 2026. They hope to establish whether INBRX-106 in conjunction with Keytruda offers greater efficacy and clinical benefits compared to existing standard care protocols.

Ozekibart Progress Update

Moving onto ozekibart, Inhibrx reported the completion of patient enrollment for the Phase 1/2 trial evaluating the treatment in combination with FOLFIRI for patients with heavily pretreated advanced or metastatic colorectal cancer. The study included 44 participants and preliminary results indicate that the combination therapy was well tolerated, displaying durable responses and a high rate of disease control.

The progression-free survival data is expected to mature in the second quarter of 2026, with plans for an update during that timeframe. Furthermore, Inhibrx is nearing completion of enrollment for a different Phase 1/2 trial analyzing ozekibart alongside irinotecan and temozolomide for patients with advanced, unresectable, relapsed, or refractory Ewing sarcoma, projected to finish in mid-2026. If trends of positive responses persist, the company intends to engage with the FDA later in 2026 to discuss potential expedited approval pathways for this treatment.

Innovative Therapeutics Overview

About INBRX-106: The INBRX-106 therapeutic is an engineered, hexavalent sdAb-based candidate specifically targeting OX40, intended to boost the activity of this co-stimulatory receptor. Its current clinical trials revolve around locally advanced or metastatic solid tumors, particularly focusing on HNSCC and NSCLC.

About ozekibart (INBRX-109): Ozekibart is described as a tetravalent antibody that functions as a death receptor 5 (DR5) agonist, capitalizing on the tumor-specific death induced by DR5 activation. Notably, a successful single-agent registration study in chondrosarcoma has already been reported, with a Biologics License Application (BLA) filing anticipated by early Q2 2026.

Conclusion

Inhibrx Biosciences remains committed to its mission of addressing complex cancer biology through innovative protein engineering methods. With promising clinical trial results on the horizon, the company is poised for significant developments in its therapeutic pipeline. To follow their progress, visit Inhibrx's official website.

• ---

Disclaimer: This press release may contain forward-looking statements regarding Inhibrx's future performance. Such statements are subject to risks and uncertainties that could cause actual results to differ materially.